TL;DR
The STREAM trial found that, among adults 70 and older with multiple chronic conditions and no known cardiovascular disease, stopping statins met its prespecified non-inferiority criterion for event-free survival over two years. However, cardiovascular events were numerically more common after discontinuation, and stopping treatment did not improve measured quality-of-life outcomes. The findings support individualized decisions, not routine statin withdrawal.
A European randomized trial found that adults aged 70 and older taking statins to prevent a first cardiovascular event could stop the medication without failing the study’s two-year non-inferiority test for event-free survival. But cardiovascular events were numerically more frequent among those who discontinued, and stopping statins did not improve measured quality-of-life outcomes, leaving the results short of a clear case for routine withdrawal.
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The STREAM trial enrolled 1,880 people aged 70 or older who had at least two chronic conditions, were taking statins for primary prevention and had no established cardiovascular disease. Participants were assigned to stop or continue treatment. The study was conducted in Europe from 2021 to 2025; the cohort’s average age was 77.5, and 46.9% were women.
Over two years, mean event-free survival was 96.5 weeks after discontinuation and 98.5 weeks with continuation. The trial met its prespecified non-inferiority criterion, with P<0.001. That result means discontinuation met the study’s statistical test against a defined margin; it does not establish that the two approaches have identical risks or that stopping is preferable.
The primary composite of heart attack, ischemic stroke or death occurred in 10.7% of the discontinuation group and 8.2% of the continuation group. Across the available follow-up, a median of 103 weeks, cardiovascular events were 12.7% and 9.2%, respectively. These differences were numerical; the report described the uptick in risk as not statistically significant. The study also found no improvement in patient-centered outcomes, including pain, falls or sarcopenia, after stopping treatment.
The Trade-Off Behind Statin Withdrawal
For older adults taking statins to prevent a first cardiovascular event, STREAM addresses a common clinical decision: whether a long-term preventive medicine still fits a person’s health, priorities and expected lifespan. Its findings suggest that stopping may be an acceptable option for some patients, but they do not show that withdrawal improves how patients feel or that cardiovascular risk is unchanged.
The event rates matter alongside the non-inferiority result. The discontinuation group had a higher numerical rate of cardiovascular events, and investigators estimated one additional event over two years for every 40 people who stopped. That estimate should be read with the trial’s population, follow-up and statistical uncertainty in mind; it is not a prediction for every older patient. The practical implication is a clinician-patient discussion weighing possible preventive benefit against treatment burden and competing health risks.
Products Worth Considering

OMRON Complete 2-in-1 Upper Arm Blood Pressure Monitor with EKG

Therabody SmartGoggles 2nd Generation Heated Eye and Temple Massager

Philips Sonicare DiamondClean 9500 Electric Toothbrush, Black, with 3 Brush Heads
As an affiliate, we earn on qualifying purchases.
Who Took Part in STREAM
STREAM studied primary prevention: participants were taking statins without a history of cardiovascular disease. More than half were recruited through primary care rather than hospitals, nearly one-third had diabetes, and more than one-quarter had been prescribed high-intensity statins. Their average baseline LDL cholesterol was 88.9 mg/dL in each study arm.
In a subgroup of 235 participants whose lipids were measured at 12 months, LDL cholesterol averaged 176.0 mg/dL after discontinuation and 99.4 mg/dL with continued treatment. The trial’s authors discussed biological pathways that could contribute to cardiovascular risk after stopping, but this proposed explanation does not establish why individual events occurred. STREAM follows the SITE/SAGA discontinuation trial, which also reported no quality-of-life improvement; that earlier study did not reach its planned enrollment.
“Statin discontinuation is “generally safe.””
— Nicolas Rodondi, MD, MAS, of Inselspital, University of Bern, presenting STREAM at the AHA meeting
Limits on Applying the Results
The study was open-label, so participants and clinicians knew whether statins had been stopped or continued. Investigators also reported substantial crossovers, which can complicate comparisons between assigned groups. The trial was not designed to prove that discontinuation is risk-free, and its results cover a selected group of older adults with multiple chronic conditions rather than all people over 70.
The cardiovascular event differences were numerical and were not reported as statistically significant. The supplied results do not establish which individuals are most likely to benefit from continuing or stopping, despite reported subgroup findings. Nor do they show that people stopping statins will experience a particular LDL change: the 12-month lipid results came from a subset. The effects of other cardiovascular preventive medications during follow-up may also have influenced outcomes, the investigators said.
More Trials and Individual Reviews
The investigators said further randomized studies should examine discontinuation of specific medicines and track other cardiovascular preventive treatments, which could affect comparisons. No additional STREAM follow-up or next trial date was specified in the report.
For now, the findings support a patient-specific review rather than automatic stopping or continuation. Clinicians and patients can weigh the person’s cardiovascular risk, other illnesses, expected lifespan, medication burden and preferences. STREAM does not provide a universal rule for deprescribing statins in older adults.
Key Questions
Does STREAM show that older adults can safely stop statins?
The trial met its two-year non-inferiority criterion for event-free survival after discontinuation. That does not prove there is no added risk: cardiovascular events were numerically more common in the discontinuation group, and the study involved a specific group of older adults.
Did stopping statins improve quality of life?
No improvement was found in the measured patient-centered outcomes, including pain, falls and sarcopenia. The results do not support stopping statins as a way to improve those outcomes in the people studied.
Who was included in the trial?
STREAM enrolled 1,880 adults aged 70 or older with at least two chronic conditions, no established cardiovascular disease and a statin prescription for primary prevention. The results may not apply to people with a prior heart attack, stroke or other established cardiovascular disease.
Should patients stop their statins based on this study?
The study does not recommend that everyone stop or continue. It supports discussing the decision with a clinician, taking account of individual cardiovascular risk, health status, treatment burden and preferences.
Source: medpagetoday.com
